On May 29, 2018 Splash Pharmaceuticals, Inc. ("Splash"), a closely held private biopharmaceutical company that develops novel cancer therapies, reported the presentation of an abstract related to the clinical trial of SPL-108 in platinum-resistant ovarian cancer patients (Press release, Splash Pharmaceuticals, MAY 29, 2018, View Source [SID1234526926]). The Phase I trial is being conducted at Rutgers Cancer Institute of New Jersey, a National Cancer Institute-designated Comprehensive Cancer Center, and the abstract will be presented by its first author Dr. Eugenia Girda, a member of the Institute’s Gynecologic Oncology Program.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation Details:
American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2018 Annual meeting in Chicago, IL.
Poster Discussion: Monday June 4, 2018 from 1:15 p.m. – 4:45 p.m. (CDT)
An Open-label Phase 1 Trial of the Safety and Efficacy of Daily Subcutaneous SPL-108 Injections When Used in Combination with Paclitaxel in Patients with Platinum-resistant, CD44+, Advanced Ovarian Epithelial Cancer.
Poster Presentation: Abstract #TPS5608, Poster Board #331a, Hall A